Mounjaro™ (tirzepatide) injection

2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Tirzepatide: Use in Patients With Hepatitis

Tirzepatide has not been studied in people with hepatitis.


Detailed Information

There is no information on the use of tirzepatide in patients with hepatitis because patients were excluded from tirzepatide clinical trials if they had acute or chronic hepatitis, signs and symptoms of any liver disease other than NAFLD, or ALT ≤3.0 times the ULN. Patients with NAFLD were eligible to participate in this trial if their ALT was ≤3.0 times the ULN.


ALT = alanine aminotransferase

NAFLD = nonalcoholic fatty liver disease

ULN = upper limit of normal

Date of Last Review: March 19, 2021

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical